
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Treatment Recommendations Upon Metastasis in CRPC
mCRPC Treated With Radium-223 Therapy
January 2015
H&P:
Imaging:
April 2016
October 2016



